The advent of highly active anti-retroviral therapy (HAART) has dramatically influenced the AIDS epidemic in developed countries. HAART treatment suppresses HIV replication, thereby preventing further immune destruction. However, many patients have a limited immune recovery due to the immune degradation imparted from the direct and indirect effects of the previously untreated chronic viral infection. We hypothesize that an effective immune therapy provided concurrently with HAART will result in a more functionally complete immune recovery and a better prognosis for HIV+ patients. Previous studies supported by this grant investigated immune dysfunction in HIV+ patients and SIV+ macaques. Here we utilize this knowledge to test a potential immune therapeutic in the SIV/macaque model. The immune therapeutic to be assessed is the cytokine interleukin (IL)-7, which normally functions as a homeostatic regulator to maintain steady T-cell levels. Compared to other immune therapeutic candidates IL-7 is unique in that it has the ability to impact T-cell renewal in the periphery as well as thymocyte maturation and T-cell production in the thymus. The general approach used here will be to treat SIV+ macaques with HAART alone or HAART with IL-7, to evaluate the ability of IL-7 to influence immune reconstitution. One of the strengths of this proposal is that IL-7 therapy will be assessed in macaques that are HAART treated both during the acute as well as during the chronic phase of the infection.
Aim 1 will assess the effect of IL-7 on T-cell phenotypes, proliferation and thymic production in HAART treated SIV infected macaques.
Aim 2 will evaluate any potentially negative effects of the IL-7 therapy through an assessment of viral replication and cell types infected.
Aim 3 will determine if IL-7 administration increases the levels of SIV specific T-cells and improves clinical outcome after cessation of HAART. We anticipate that use of the SIV/macaque model will dramatically assist in the approval of IL-7 as an immune therapeutic for HIV infected patients as well as identify the patient populations most likely to benefit from this therapy. Furthermore, these studies may indicate the means by which IL-7 therapy may assist other T-cell depleting conditions such as those following chemotherapy and bone marrow transplantation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI035522-13
Application #
6848316
Study Section
Special Emphasis Panel (ZRG1-AARR-2 (02))
Program Officer
Voulgaropoulou, Frosso
Project Start
1994-05-01
Project End
2007-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
13
Fiscal Year
2005
Total Cost
$548,861
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Kuhrt, David; Faith, Seth; Hattemer, Angela et al. (2011) Naïve and memory B cells in the rhesus macaque can be differentiated by surface expression of CD27 and have differential responses to CD40 ligation. J Immunol Methods 363:166-76
Kuhrt, David; Faith, Seth A; Leone, Amanda et al. (2010) Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population. J Virol 84:2466-76
Leone, Amanda; Rohankhedkar, Mukta; Okoye, Afam et al. (2010) Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. J Immunol 185:1650-9
Pandrea, Ivona; Sodora, Donald L; Silvestri, Guido et al. (2008) Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol 29:419-28
Kosub, David A; Lehrman, Ginger; Milush, Jeffrey M et al. (2008) Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections. J Virol 82:1155-65
Kosub, David A; Durudas, Andre; Lehrman, Ginger et al. (2008) Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques. Curr HIV Res 6:520-30
Gordon, Shari N; Klatt, Nichole R; Bosinger, Steven E et al. (2007) Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 179:3026-34
Estes, Jacob D; Wietgrefe, Stephen; Schacker, Timothy et al. (2007) Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 195:551-61
Milush, Jeffrey M; Reeves, Jacqueline D; Gordon, Shari N et al. (2007) Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host. J Immunol 179:3047-56
Milush, Jeffrey M; Stefano-Cole, Kelly; Schmidt, Kimberli et al. (2007) Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques. J Virol 81:6175-86

Showing the most recent 10 out of 57 publications